metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mGC or mGEJC - L1 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - PDL1 positive
versus placebo plus SoC
	pembrolizumab alone
	KEYNOTE-062 (P vs C ; CPS>10), 2020 JAMA Oncol 2020 Sep 3;6(10):1-10. Journal of Clinical Oncology NCT02494583	RCT	mGC or mGEJC - L1 - PDL1 positive	pembrolizumab	placebo plus chemotherapy (cisplatin plus fluorouracil or capecitabine)	first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (PDL1 CPS>10)	92 / 90	some concern	suggested	suggested 31 % decrease in deaths (OS) (PE)
	pembrolizumab plus SoC
	KEYNOTE-062 (PC vs C ; CPS>1), 2020 JAMA Oncol 2020 Sep 3;6(10):1-10. Journal of Clinical Oncology NCT02494583	RCT	mGC or mGEJC - L1 - PDL1 positive	pembrolizumab plus 5FU or capcitabine plus cisplatine	placebo plus 5FU or capcitabine plus cisplatine	first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma	257 / 250	low	inconclusive	inconclusive 15 % decrease in deaths (OS) (PE) inconclusive 16 % decrease in progression or deaths (PFS) (PE)
	KEYNOTE-062 (PC vs C ; CPS>10), 2020 JAMA Oncol 2020 Sep 3;6(10):1-10. Journal of Clinical Oncology NCT02494583	RCT	mGC or mGEJC - L1 - PDL1 positive	pembrolizumab plus chemotherapy (5FU or capecitabine, plus cisplatine)	placebo plus chemotherapy (5FU or capecitabine, plus cisplatine)	first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (PDL1 CPS>10)	99 / 90	low	suggested	inconclusive 15 % decrease in deaths (OS) (PE)
versus Standard of Care (SoC)
	pembrolizumab alone
	KEYNOTE-062 (P vs C ; CPS>1), 2020 JAMA Oncol 2020 Sep 3;6(10):1-10. Journal of Clinical Oncology NCT02494583	RCT	mGC or mGEJC - L1 - PDL1 positive	pembrolizumab	placebo plus chemotherapy (5FU or capecitabine plus cisplatin)	first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma	256 / 250	some concern	inconclusive	statistically significant 66 % increase in progression or deaths (PFS) statistically significant 71 % decrease in objective responses (ORR)